Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal
Completed
- Conditions
- Hypercholesterolemia
- Registration Number
- NCT00240344
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to determine the efficacy of Crestor in high risk patients switched from higher doses of other statins in obtaining the new European Atherosclerosis Society (EAS) low-density lipoprotein cholesterol (LDL-C) guidelines.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2650
Inclusion Criteria
- High risk patients
- High doses of other statins
- LDL-C known, starts with Crestor 10 mg
- Permission to use patient data by AstraZeneca (AZ)
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Crestor's efficacy in lowering LDL-C in high risk hypercholesterolemia patients?
How does Crestor compare to other statins in achieving EAS LDL-C targets in high risk cardiovascular patients?
Which biomarkers correlate with LDL-C reduction success in patients switched to Crestor from higher dose statins?
What adverse event profiles are associated with statin switching to Crestor in hypercholesterolemia management?
How do combination therapies with Crestor impact lipid management in patients with familial hypercholesterolemia?
Trial Locations
- Locations (1)
Research Site
🇳🇱Zwolle, Netherlands
Research Site🇳🇱Zwolle, Netherlands